TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34049532

Group type: EXPERIMENTAL
Intervention: Cogniaction project intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32419281

Group type: EXPERIMENTAL
Intervention: Isoflavones (100 mg daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32758312

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE-A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Supportive counselling (SC)
Number of subjects: 63
Study: 35315908

Group type: EXPERIMENTAL
Intervention: Regional Anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age, Preoperative Delirium, Preexisting Dementia, Center
Number of subjects: 0
Study: 32340841

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32936442

Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diet with 2% more soluble fibers (SF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diet with 4% more soluble fibers (SF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diet with 2% more insoluble fibers (ISF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diet with 4% more insoluble fibers (ISF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Body weight gain (BWG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma cholesterol concentration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concentration of HDL and LDL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blood concentration of triglyceride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blood concentration of VLDL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma enzyme activity of ALT
Number of subjects: 30
Study: 33394814

Group type: EXPERIMENTAL
Intervention: Hair analysis
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Self-reported drug use by questionnaires
Number of subjects: 69
Study: 32339768

Group type: EXPERIMENTAL
Intervention: Risk Reduction through Family Therapy (RRFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36151949

Group type: EXPERIMENTAL
Intervention: Bronchial washing using a 4.0-mm thin bronchoscope under virtual bronchoscopic navigation guidance
Number of subjects: 85

Group type: COMPARATOR
Intervention: Bronchial washing using a 5.9-mm conventional bronchoscope
Number of subjects: 85
Study: 33976537

Group type: EXPERIMENTAL
Intervention: High-dose lidocaine (Group HL: 1.5 mg/kg bolus followed by an infusion at 2.0 mg/kg/hour)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low-dose lidocaine (Group LL: 1.5 mg/kg bolus followed by an infusion at 1.0 mg/kg/hour)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (Group C: received a volume-matched normal saline at the same rate)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: High-dose lidocaine (Group HL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine groups (both HL and LL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine administration
Number of subjects: 135
Study: 32887655

Group type: EXPERIMENTAL
Intervention: Stakeholder‐driven Community Diffusion Survey (SDCD)
Number of subjects: 10
Study: 35234723

Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 51
Study: 33430927

Group type: EXPERIMENTAL
Intervention: Immunosuppression guided by TTV monitoring in addition to conventional therapeutic drug monitoring of tacrolimus trough levels
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional therapeutic drug monitoring
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Immunosuppression guided by TTV monitoring
Number of subjects: 144
Study: 34260478

Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet including ½ cup (86 g) of cooked soybeans daily for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: No diet changes for 12 weeks
Number of subjects: 38
Study: 32077907

Group type: EXPERIMENTAL
Intervention: Initial observation with aflibercept only if visual acuity (VA) worsened
Number of subjects: 236

Group type: COMPARATOR
Intervention: Initial observation
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Baseline central subfield thickness at least 300 μm
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Moderately severe nonproliferative diabetic retinopathy (ETDRS level 47 and above)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Nonstudy eye received DME treatment within 4 months of randomization
Number of subjects: 236
Study: 35794673

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1 g 4 times a day
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 32402480

Group type: EXPERIMENTAL
Intervention: 2.5 mg i.v. haloperidol
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 36476361

Group type: EXPERIMENTAL
Intervention: Full-endoscopic disc decompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microsurgical disc decompression
Number of subjects: 0
Study: 33395437

Group type: EXPERIMENTAL
Intervention: COTiD-UK (Community Occupational Therapy for people with dementia)
Number of subjects: 468

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 468
Study: 32252062

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) infusion
Number of subjects: 34
Study: 35471655

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (20 l · min‐1 with 40% oxygen concentration) with head-of-bed elevation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (20 l · min‐1 with 40% oxygen concentration) without head-of-bed elevation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Head-of-bed elevation alone (control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula with head-of-bed elevation compared to high-flow nasal cannula alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (alone or in combination with head-of-bed elevation)
Number of subjects: 23
Study: 32829585

Group type: EXPERIMENTAL
Intervention: Duplexed real-time PCR approach using LNA-modified primers
Number of subjects: 753
Study: 32127335

Group type: EXPERIMENTAL
Intervention: Fish oil (2000 mg docosahexaenoic acid + 400 mg eicosapentaenoic acid/day)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Curcumin (160 mg/day)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combination of fish oil and curcumin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 152
Study: 35325628

Group type: EXPERIMENTAL
Intervention: REACT programme (12-month community-based group physical activity and behaviour maintenance intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 33330909

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) catheter ablation
Number of subjects: 255

Group type: COMPARATOR
Intervention: Antiarrhythmic drug (AAD) therapy
Number of subjects: 255
Study: 32600489

Group type: EXPERIMENTAL
Intervention: Telephone-based peer volunteer support intervention
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Volunteers' experiences providing support
Number of subjects: 574
Study: 34131051

Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 92
Study: 34689732

Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T) intervention
Number of subjects: 4320

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 4320
Study: 33829299

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT)
Number of subjects: 39
Study: 33079154

Group type: EXPERIMENTAL
Intervention: 40 mg of praliciguat daily for 12 weeks (n=91)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo for 12 weeks (n=90)
Number of subjects: 196
Study: 34116619

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAA)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 398
Study: 32131876

Group type: EXPERIMENTAL
Intervention: Nurse-led health coaching program
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 140
Study: 35795714

Group type: EXPERIMENTAL
Intervention: IVIG (400 mg/kg daily for five consecutive days starting at 4-6 weeks of gestation)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IVIG (400 mg/kg daily for five consecutive days starting at 4-5 weeks of gestation)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 102
Study: 34270930

Group type: EXPERIMENTAL
Intervention: Oral administration of Lactobacillus casei Zhang (L. casei Zhang)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33196565

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatic-anesthetic (Mydrane/Fydrane)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical eyedrops only (Control)
Number of subjects: 50
Study: 32610451

Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics approach with IMS-HRMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33634869

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg (Pem100)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg (Pem200)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg (Pem100) with chemotherapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg (Pem200) with chemotherapy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cost analysis for Pembrolizumab 100 mg (Pem100)
Number of subjects: 114
Study: 36167573

Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole 960 mg once daily for 18 months
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo once daily for 18 months
Number of subjects: 432
Study: 33085707

Group type: EXPERIMENTAL
Intervention: Higher reward size
Number of subjects: 149

Group type: COMPARATOR
Intervention: Lower reward size
Number of subjects: 149
Study: 34915468

Group type: EXPERIMENTAL
Intervention: Detectable breath CH4
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Decrease in breath CH4 over time
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Larger drop in CH4
Number of subjects: 1126
Study: 34776207

Group type: EXPERIMENTAL
Intervention: Core stability exercises
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sensory-motor exercises
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 35633124

Group type: EXPERIMENTAL
Intervention: NOAC (rivaroxaban, apixaban)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional treatment (low molecular weight heparin and vitamin K antagonists)
Number of subjects: 200
Study: 32393412

Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 281
Study: 33472925

Group type: EXPERIMENTAL
Intervention: Preconditioned autologous MSC injections
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 54
Study: 33324969

Group type: EXPERIMENTAL
Intervention: Nested trial designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonnested trial designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite data-set designs
Number of subjects: 0
Study: 32828488

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptides (14 trials; n=2207)
Number of subjects: 56047

Group type: EXPERIMENTAL
Intervention: Inodilators (13 trials; n=2941)
Number of subjects: 56047

Group type: EXPERIMENTAL
Intervention: Vasopressors (4 trials; n=1047)
Number of subjects: 56047

Group type: EXPERIMENTAL
Intervention: Nitric oxide donors, alpha‐2‐agonists, and calcium channel blockers
Number of subjects: 56047
Study: 36357795

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide (3 doses of 50 µg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 34491267

Group type: EXPERIMENTAL
Intervention: Awake DBS (local anesthesia)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Asleep DBS (general anesthesia)
Number of subjects: 110
Study: 35817419

Group type: EXPERIMENTAL
Intervention: CONVEX (n=15)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CONCAVE (n=16)
Number of subjects: 47

Group type: COMPARATOR
Intervention: CONTROL (n=16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CONVEX
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CONCAVE
Number of subjects: 47

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 47
Study: 33807731

Group type: EXPERIMENTAL
Intervention: Beta-hydroxybutyrate salts
Number of subjects: 22

Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 22
Study: 32921989

Group type: COMPARATOR
Intervention: Dexmedetomidine 2 μg kg−1 (Group D)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg kg−1 and ketamine 2 mg kg−1 (Group DK)
Number of subjects: 66
Study: 33269395

Group type: EXPERIMENTAL
Intervention: Vortioxetine plus celecoxib
Number of subjects: 122

Group type: COMPARATOR
Intervention: Vortioxetine plus placebo
Number of subjects: 122
Study: 32623288

Group type: EXPERIMENTAL
Intervention: Panitumumab-based treatment (induction with panitumumab-FOLFOX followed by maintenance with single-agent panitumumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent panitumumab (after 4-month induction with panitumumab-FOLFOX)
Number of subjects: 0
Study: 32326749

Group type: EXPERIMENTAL
Intervention: START program
Number of subjects: 8
Study: 32016367

Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of electronic health records (EHRs) for patient recruitment and follow-up
Number of subjects: 0
Study: 34927539

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 46

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 46
Study: 32057631

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 47
Study: 33463020

Group type: EXPERIMENTAL
Intervention: Internet-based exercise training (IBET)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Standard physical therapy (PT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard physical therapy (PT) or internet-based exercise training (IBET)
Number of subjects: 350
Study: 34131186

Group type: EXPERIMENTAL
Intervention: FSMS-RUTF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSMS-RUTF
Number of subjects: 0

Group type: COMPARATOR
Intervention: PM-RUTF
Number of subjects: 0
Study: 32382926

Group type: EXPERIMENTAL
Intervention: Potassium oxalate (Oxa‐Gel BF)
Number of subjects: 74

Group type: COMPARATOR
Intervention: GaAlAs low‐power laser (100 mW, 808nm, 60 J/cm2)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Potassium oxalate (Oxa‐Gel BF) associated with GaAlAs low‐power laser
Number of subjects: 74

Group type: COMPARATOR
Intervention: All groups (G1, G2, G3)
Number of subjects: 74
Study: 35672866

Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil (6.2 g daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no fish oil)
Number of subjects: 40
Study: 32464903

Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside, 20 mg/kg
Number of subjects: 102

Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 102
Study: 34148021

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication adherence
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Single antihypertensive medication
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Multiple antihypertensive medications
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Preferred classes of antihypertensive drugs
Number of subjects: 1479
Study: 32371681

Group type: EXPERIMENTAL
Intervention: Hyper-selective posterior fusion (UIV = UEV, LIV = LEV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hyper-selective posterior fusion (UIV = UEV-1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hyper-selective posterior fusion (UIV = UEV)
Number of subjects: 80
Study: 34665853

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive‐Behavioral Social Skills Training and Compensatory Cognitive Training (CBSST‐CCT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Goal‐focused Supportive Contact (SC)
Number of subjects: 55
Study: 34713983

Group type: EXPERIMENTAL
Intervention: TT+RT (testosterone treatment + resistance training)
Number of subjects: 13

Group type: COMPARATOR
Intervention: no-TT (testosterone treatment only)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TT+RT
Number of subjects: 13

Group type: COMPARATOR
Intervention: no-TT
Number of subjects: 13
Study: 32112166

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine with intravenous analgesia (ITM-IV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intravenous analgesia without intrathecal morphine (IV)
Number of subjects: 36
Study: 34210788

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 36166405

Group type: EXPERIMENTAL
Intervention: Single high dose (10 mg/kg) of liposomal amphotericin B with optimized oral backbone of fluconazole and flucytosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHO-recommended regimen of seven days of amphotericin B deoxycholate plus flucytosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single high dose (10 mg/kg) of liposomal amphotericin B
Number of subjects: 0
Study: 33940487

Group type: EXPERIMENTAL
Intervention: Self-monitoring group (SMG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 34
Study: 35964042

Group type: EXPERIMENTAL
Intervention: Physical Activity Referral Scheme (PARS)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Physical Activity Advice (PAA)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: PARS
Number of subjects: 567

Group type: COMPARATOR
Intervention: PAA
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: PARS and PAA
Number of subjects: 567
Study: 34684496

Group type: EXPERIMENTAL
Intervention: Mixed dietary pattern
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Traditional, vegetarian-alike dietary pattern
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lifestyle Index
Number of subjects: 202
Study: 33284338

Group type: EXPERIMENTAL
Intervention: CYP test-guided (CTG)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Structured clinical monitoring (SCM)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: CTG among extreme metabolizers
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: SCM among extreme metabolizers
Number of subjects: 528
Study: 35218356

Group type: EXPERIMENTAL
Intervention: Second dose of measles vaccine (MV2) at 18 months of age
Number of subjects: 3164

Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Second dose of measles vaccine (MV2) after OPV campaigns
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Second dose of measles vaccine (MV2)
Number of subjects: 3164
Study: 33138210

Group type: EXPERIMENTAL
Intervention: High personalization (structured video calls with a dietitian using the AES report plus dietary self‐monitoring with text message feedback)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High personalization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low personalization (web‐based personalized nutrition feedback report using AES data)
Number of subjects: 50
Study: 36127742

Group type: EXPERIMENTAL
Intervention: Symptom assessment application (SAA) usage
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard care without using a SAA
Number of subjects: 440
Study: 33359350

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 35388309

Group type: EXPERIMENTAL
Intervention: Date Palm Pollen (DPP) 3 grams twice a day for two months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 60
Study: 34475139

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 32193662

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 20
Study: 36401339

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) 240 mg twice daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 33031534

Group type: EXPERIMENTAL
Intervention: Active choice intervention
Number of subjects: 11693

Group type: EXPERIMENTAL
Intervention: Passive choice intervention
Number of subjects: 11693

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11693
Study: 33184146

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 60,000 IU daily for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33873106

Group type: EXPERIMENTAL
Intervention: Flywheel loading conditions
Number of subjects: 23
Study: 34293634

Group type: EXPERIMENTAL
Intervention: Home-based early stimulation program targeting visual and motor functions (ESPVM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 30
Study: 33044283

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation with driving pressure of 20 cm H2O for 2 hours (phase 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure for 2 hours (phase 3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation with driving pressure of 10 cm H2O for 4 hours (phase 4)
Number of subjects: 10